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Hodgkin’s disease mortality rates steadily declined by about 75% between the late 1960’s and the late 1990’s in the current
European Union countries and the USA, and Japan. Eastern European countries, however, showed only an approximately 40%
decline between the late 1960’s and the early 1990’s, and no further fall thereafter.
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Effective integrated chemo- and radiotherapy has made Hodgkin’s
disease (HD) a largely curable disease (Hoppe et al, 1994; La
Vecchia et al, 1991). Between 1960 and 1990 mortality from Hodg-
kin’s disease declined by over 60% in western Europe, and even to
a greater extent in the USA and Japan. However, in former non-
market economy eastern European countries the fall has been only
about 30% (Levi et al, 1995). Recent economical and social devel-
opments in several eastern European countries have been
associated with a fall in total mortality (Zatonski and Boyle,
1996; Zatonski et al, 1998) as well as in mortality from curable
neoplasm such as testicular cancer (Becker and Boyle, 1997; Levi
et al, 2001).
METHODS
We considered, therefore, recent trends in mortality from Hodg-
kin’s disease in the European Union (EU, comprising Austria,
Belgium, Denmark, Finland. France, Germany, Greece, Ireland,
Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, UK),
six eastern European countries providing data to the WHO mortal-
ity database (Bulgaria, the Czech Republic, Hungary, Poland,
Romania, Slovakia), and, for comparative purposes, the USA and
Japan. We obtained estimates of the resident population and
numbers of deaths from the WHO Database, recoding the latter
according to the Ninth Revision of the International Classiﬁcation
of Diseases. Age-adjusted rates, by 5-year age groups, were based
on the world standard population (Doll and Smith, 1982). The
methods have been discussed in detail elsewhere (Levi et al,
1999); however, mortality for HD in European countries has not
been comprehensively examined.
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Figure 1 Trends in age-adjusted (world population) overall death certi-
ﬁcation rates from Hodgkin’s disease per 100000 men (a) and women (b)
in the European Union, selected eastern European countries (Bulgaria,
Czech Republic, Hungary, Poland, Romania and Slovakia), USA and Japan,
from 1965–69 to 1995–98. Received 21 March 2002; revised 13 May 2002; accepted 13 May 2002
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Figure 1 gives trends in mortality from HD in four broad
geographic areas. In the late 1960’s, mortality rates from Hodg-
kin’s disease were very similar in the EU, eastern European
countries and the USA, i.e. around 2/100000 men and 1.2/
100000 women. Rates were appreciably lower (around 0.7/
100000 men, 0.4 for women) in Japan. In all the areas considered,
substantial falls in mortality were observed, which were earlier and
greater throughout the 1970’s and 1980’s in the USA as compared
to the EU, and only in the late 1990’s did HD mortality in the
EU (0.53/100000 men, 0.33 for women) approach that in the
USA (0.47/100000 men, 0.32 for women). The overall fall in
men between 1965 and 1998 was 74% in the EU and 77% in
the USA, and 71 and 72%, respectively, for women. Between
the late 1980’s and the late 1990’s, the fall was 40% for males
and 34% for females in the EU, 34% for males and 24% for
females in the USA. Although Japan had very low rates in the
1960’s, a further appreciable fall was observed, to reach rates of
0.08/100000 men and 0.04 for women in 1995–98.
Eastern European countries showed an approximately 40%
decline in HD mortality between the late 1960’s and the early
1990’s, to reach 1.26/100000 men and 0.68 women. However, no
appreciable further fall was observed over more recent years, and
the rates were 1.18/100000 men and 0.62 for women in 1995–98.
Table 1 shows age-adjusted death rates from HD for men and
women in 19 European countries besides the EU, USA and Japan
in 1965–69 and 1995–98. In most western European countries,
rates fell by 70–80% over the last three decades. However, the
decline in HD mortality was much less (10 to 30%) in selected
eastern European countries. About a third of patients dying from
HD are aged 15 to 44 years. The pattern of trends in the young
across most countries was similar to that for all ages. For men aged
15 to 44 the fall was 79% (from 1.9 to 0.4/100000) in the EU, 77%
(from 2.1 to 0.5/100000) in the USA, and 82% (from 0.3 to 0.1/
100000) in Japan. Corresponding values for women were 779%
(from 1.3 to 0.3/100000) in the EU, 775% (from 1.2 to 0.3/
100000) in the USA, and 780% (from 0.2 to 0.04/100000) in
Japan.
DISCUSSION
The present data indicate that HD mortality in the EU, the USA
and Japan has continued to decline, though to a smaller degree,
over more recent calendar periods, and hence conﬁrms the persis-
tence of advancements in the integrated treatment of HD. Rates are
exceedingly low in Japan, whose HD mortality was already a third
than those of North America and Europe in the 1960’s, and is now
less than a ﬁfth than in other developed areas of the world. It is
unlikely that differences in death certiﬁcation validity and accuracy
can explain such large differences.
The decline in HD mortality was similar in the older age groups,
while for leukaemias the falls tend to be greater at younger age
(Levi et al, 2000). This suggests that advancements in treatment
for HD had a favourable impact also in the elderly.
In eastern Europe, there has been not only a substantial delay in
the fall of HD mortality, but no progress has been observed during
the 1990’s, although efﬁcacious chemotherapy schemes for HD
(Hoppe et al, 1994), as well as radiotherapy, should, in principle,
now be available in those countries, too. These unfavourable trends
contrast with the declines in mortality from cardiovascular diseases
and total mortality observed from the early 1990’s onwards in
Poland, Hungary, the Czech Republic and other major eastern
European countries (Zatonski and Boyle, 1996 ; Zatonski et al,
1998). Thus, over a thousand potentially avoidable deaths per year
from HD, largely at younger ages, with an associated loss of many
decades of life expectancy, are still taking place in these countries
every year.
As already observed for childhood leukaemia (La Vecchia et al,
1998; Levi et al, 2000) and testicular cancer (Levi et al, 2001), the
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Table 1 Trends in age-adjusted (world population) overall death certiﬁcation rates per 100000 men and women and average annual number of certiﬁed
deaths from Hodgkin’ disease in the European Union, Eastern countries (Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia), the USA, Japan
and 19 European countries between 1965–69 and 1995–98 (unless otherwise speciﬁed in parenthesis)
Males Females
1965–69 1995–98 1965–69 1995–98
Country Rate No. of deaths Rate No. of deaths % Change Rate No. of deaths Rate No. of deaths % Change
European Union 2.0 3270 0.5 1422 773.6 1.1 2144 0.3 1127 771.1
Eastern Countries 2.1 546 1.2 655 742.9 1.0 311 0.6 417 740.0
USA 2.0 2053 0.5 773 776.5 1.2 1356 0.3 626 772.2
Japan (95–97) 0.7 318 0.1 73 788.6 0.4 187 0.0 43 788.9
Austria 2.6 106 1.0 58 760.4 1.5 82 0.7 55 755.3
Belgium (95) 2.2 123 0.5 31 779.4 1.3 77 0.3 24 777.2
Bulgaria 1.5 68 1.2 64 718.6 0.7 36 0.5 32 727.0
Denmark (95–96) 2.3 65 0.8 30 763.6 1.2 34 0.4 16 769.0
Finland 1.9 44 0.4 14 778.0 1.1 31 0.3 13 774.3
France 1.5 417 0.4 171 772.7 0.9 271 0.2 119 774.2
Germany 2.1 849 0.5 302 776.1 1.3 605 0.3 277 773.6
Greece 1.9 87 1.3 104 730.1 0.9 47 0.7 69 718.4
Hungary (70–74) 1.1 65 1.0 61 710.4 0.6 41 0.6 49 0.0
Ireland (95–97) 1.9 30 0.8 17 760.3 1.2 17 0.3 8 771.8
Italy 2.6 739 0.5 227 779.1 1.5 488 0.3 175 778.0
Netherlands 2.2 145 0.4 45 780.3 1.2 86 0.3 41 775.8
Norway (95–97) 2.0 45 0.4 12 780.8 1.3 34 0.3 10 779.2
Poland (95–96) 1.8 270 1.4 310 719.1 0.9 153 0.7 186 717.2
Romania (70–74) 1.3 137 1.0 127 723.4 0.6 72 0.6 83 78.3
Spain 1.4 227 0.6 151 758.8 0.7 128 0.3 112 751.5
Sweden (95–96) 1.9 94 0.3 21 785.4 1.2 64 0.3 27 774.1
Switzerland (90–94) 2.3 76 0.8 37 766.4 1.4 51 0.5 27 766.9
United Kingdom 2.1 633 0.5 183 777.7 1.1 404 0.3 141 773.2
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British Journal of Cancer (2002) 87(3), 291–293 ã 2002 Cancer Research UKfall in mortality for HD has been earlier and greater in North
America than in western Europe. Even to a more dramatic extent
than for childhood leukaemias or testicular cancer, the present data
indicate that substantial inadequacies are persistent in the manage-
ment of curable neoplasms in eastern European countries, pointing
to the need for a rational organization of cancer control and treat-
ment in those countries.
ACKNOWLEDGEMENTS
This work was supported by the Swiss League against Cancer and
the Italian Association for Cancer Research.
REFERENCES
Becker N, Boyle P (1997) Decline in mortality from testicular cancer in West
Germany after reuniﬁcation. Lancet 350: 744
Doll R, Smith PG (1982) Comparison between registries: age-standardized
rates. In. Cancer Incidence in Five Continents, Vol. IV (Waterhouse JAH,
Muir CS, Shanmugaratnam K, Powell J, Peacham D, Whelan S (eds);
pp. 671–675 IARC Scientiﬁc Publication No 42. Lyon IARC
Hoppe RT, Hanton, AL, Hanks GE, Owen BO (1994) Progress in the treat-
ment of Hodgkin’s disease in the United States, 1973 versus 1983.
Cancer 74: 3198–3203
La Vecchia C, Levi F, Lucchini F, Kaye SB, Boyle P (1991) Hodgkin’s mortal-
ity in Europe. Br J Cancer 64: 723–734
La Vecchia C, Levi F, Lucchini F, Lagiou P, Trichopoulos D, Negri E (1998)
Trends in childhood cancer mortality as indicators of quality of medical
care in the developed world. Cancer 83: 2223–2227
Levi F, La Vecchia C, Lucchini F, Te VC, Franceschi S (1995) Mortality from
Hodgkin’s disease and other lymphomas in Europe, 1960-1990. Oncology
52: 93–96
Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C (1999) Cancer mortality in
Europe, 1990–94, and an overview of trends 1955 to 1994. Eur J Cancer
35: 1477–1516
Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C (2000) Trends in mortal-
ity from leukemia in subsequent age groups. Leukemia 14: 1980–1985
Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E (2001) Western and eastern
European trends in testicular cancer mortality. Lancet 357: 1853–1854
Zatonski WA, Boyle P (1996) Health transformations in Poland after 1988. J
Epidemiol Biostat 4: 185–193
Zatonski WA, McMichael AJ, Powles JW (1998) Ecological study of reasons
for sharp decline in mortality from ischaemic disease in Poland in 1991. Br
Med J 316: 1047–1051
E
p
i
d
e
m
i
o
l
o
g
y
Hodgkin’s disease in Europe
F Levi et al
293
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 291–293